What Is Precision Stem Cell Therapy? Why Generic Protocols Fall Short
What distinguishes a precision protocol from a standard stem cell programme? Why does individualisation matter for autism outcomes?
The Problem with Generic Protocols
Autism is not a single condition. It is a spectrum of neurological differences with diverse underlying causes — different patterns of neuroinflammation, different immune profiles, different neurotrophic factor levels, different genetic and metabolic contributions. No two autistic children have identical neurobiology.
A generic stem cell protocol — one that applies the same cell source, dose, administration route and follow-up schedule to every child — treats autism as if it were a uniform condition. It is not.
Precision stem cell therapy starts from the premise that the protocol must be designed around the individual child's biological profile. This is the same logic that drives personalised medicine in oncology — where genomic profiling shapes treatment selection — applied to neurodevelopmental intervention.
The Components of Precision
Baseline neurological mapping. Before any treatment decision, QEEG brain mapping establishes the child's individual electrical activity profile. The specific patterns of theta excess, alpha connectivity, inter-regional coherence and other markers guide decisions about protocol design and establish the baseline against which change will be measured.
Biomarker assessment. Pre-treatment blood and — where indicated — cerebrospinal fluid analysis documents inflammatory cytokine levels (IL-6, IL-1β, TNF-alpha), immune subset ratios (Treg/Th17 balance), neurotrophic factor levels (BDNF, NGF), metabolic markers and mitochondrial function indicators.
Children with high inflammatory burden and low BDNF, for example, present a different target profile than children with immune dysregulation but less inflammation. The protocol is adapted accordingly.
Cell source selection. The decision between bone marrow and adipose tissue as the source of autologous cells depends on the child's age, body composition, the targeted mechanism of action for this particular case, and logistical factors. This is not a one-size decision.
Dose and administration route. Cell concentration and administration route (intravenous, intrathecal, or combination) are determined based on profile data. Intrathecal administration places cells closer to the central nervous system but requires different procedural considerations than intravenous alone.
Preparation protocol. Some children benefit from a preparation phase prior to cell administration — nutritional, anti-inflammatory or immune-modulating support — that optimises the biological environment for cellular therapy. This varies by case.
Follow-up schedule. Post-treatment QEEG at 3, 6 and 12 months provides objective data that guides decisions about whether repeat sessions are warranted, and which supportive interventions should be prioritised in each phase.
What This Looks Like in Practice
The evaluation phase for precision therapy takes approximately 4–6 weeks from initial consultation to treatment decision. This period involves the biomarker panel, QEEG assessment, clinical review, case conference, and a detailed family discussion of findings and recommendations.
The protocol document prepared for each child specifies — in writing — the rationale for each decision: why this cell source, this dose, this administration approach, this preparation. Families receive this documentation. It is not a secret algorithm.
Why This Matters for Outcomes
The research literature on stem cell therapy for autism includes heterogeneous results: some studies show strong responses, others more modest. One contributor to this heterogeneity is protocol variation — comparing results across studies that differ significantly in cell source, dose, route and selection criteria is methodologically challenging.
Within a well-characterised precision protocol, where children are selected based on profile data and treated with individually designed approaches, the response rates are higher and more predictable than in heterogeneous generic cohorts.
Precision is not a marketing term. It is a methodological commitment with direct consequences for outcomes.